BAUSCH HEALTH COMPANIES INC/ CA0717341071 /
6/24/2022 10:00:01 PM | Chg. +1.83 | Volume | Bid10:14:59 PM | Ask10:14:59 PM | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
11.28CAD | +19.37% | 1.64 mill. Turnover: 17.93 mill. |
11.00Bid Size: 500 | 11.30Ask Size: 700 | 4.02 bill.CAD | - | - |
GlobeNewswire
2/24
Palette Life Sciences Enters Into an Agreement with Lantheus to Support the Promotion of PYLARIFY® (...
GlobeNewswire
2/24
Lantheus Holdings, Inc. Reports Fourth Quarter and Full Year 2021 Financial Results
GlobeNewswire
2/23
Nicox Announces VYZULTA Now Commercialized in 7 Territories and Approved in Further 9 Countries
GlobeNewswire
2/10
Lantheus Announces Presentation Featuring PYLARIFY® (Piflufolastat F18) at the 2022 ASCO GU Meeting
GlobeNewswire
2/10
Lantheus Holdings to Host Fourth Quarter and Full Year 2021 Earnings Conference Call and Webcast on ...
GlobeNewswire
1/27
Lantheus Collaborates with The Prostate Cancer Clinical Trial Consortium (PCCTC) To Advance AI-Enabl...
GlobeNewswire
11/22/2021
Lantheus Announces CMS Grants Transitional Pass-Through Payment for PYLARIFY® (piflufolastat F 18) I...
GlobeNewswire
11/17/2021
Lantheus Holdings Announces Presentations Featuring PYLARIFY® (Piflufolastat F 18), its PSMA-Targete...
GlobeNewswire
11/17/2021
Nicox is Granted Patent for Blepharitis Product Candidate NCX 4251 in Europe
GlobeNewswire
11/16/2021
Lantheus Holdings to Present at the 4th Annual Evercore ISI HealthCONx Conference
GlobeNewswire
11/16/2021
Clearside Biomedical Features FDA-Approved XIPERE™ in Multiple Presentations at the American Academy...
GlobeNewswire
11/4/2021
Eyenovia Announces First Patient Enrolled in Phase 3 VISION-2 Trial of MicroLine for Presbyopia